# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Deutsche Bank analyst George Hill maintains Agilon Health (NYSE:AGL) with a Hold and lowers the price target from $5 to $4.
Benchmark analyst Bill Sutherland reiterates Agilon Health (NYSE:AGL) with a Buy and maintains $9 price target.
RBC Capital analyst Sean Dodge reiterates Agilon Health (NYSE:AGL) with a Outperform and maintains $8 price target.
Agilon Health (NYSE:AGL) reported quarterly sales of $1.483 billion which missed the analyst consensus estimate of $1.560 billi...
Evercore ISI Group analyst Elizabeth Anderson maintains Agilon Health (NYSE:AGL) with a In-Line and raises the price target ...